Penumbra vs Tandem Diabetes Care
Penumbra reported revenue of $1.4 billion in fiscal 2025, 1.4 times Tandem Diabetes Care's $1.0 billion in fiscal 2025. Penumbra's revenue grew 17.5% in its latest year, and Tandem Diabetes Care's grew 7.9%. Penumbra had an operating margin of 13.5%, against -18.4% at Tandem Diabetes Care. Free cash flow was $175 million at Penumbra and −$30 million at Tandem Diabetes Care.
Side by side
| Penumbra | Tandem Diabetes Care | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $1.4B | $1.0B |
| Revenue growth | 17.5% | 7.9% |
| Revenue growth a year, last 5 years | 20.2% | 15.3% |
| Gross margin | 67.1% | 53.8% |
| Operating margin | 13.5% | −18.4% |
| Net margin | 12.7% | −20.2% |
| Free cash flow | $175M | −$30M |
| Free cash flow margin | 12.5% | −2.9% |
| Return on capital | 18.8% | −85.5% |
| Net debt to EBITDA | −2.5x | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 0.1% | 2.8% |
| Last close | $319.21 | $16.91 |
| P/E at the last close | 80.4× | — |
| Insider trades, last 12 months | sold $11.0 million | sold $36,911 |
| Piotroski F-score | 7 of 9 | 4 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
PenumbraTandem Diabetes Care
Operating margin
Percent of revenue
PenumbraTandem Diabetes Care
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
PenumbraTandem Diabetes Care
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Penumbra and Tandem Diabetes Care pages.